Search

1. Alternative pricing models for remdesivir and other potential treatments for COVID-19

Author(s):

Whittington, Melanie D., author
Campbell, Jonathan D., author

Publication:

[Boston, Massachusetts] : Institute for Clinical and Economic Review, June 24, 2020

Subject(s):

Antiviral Agents -- economics
Coronavirus Infections -- drug therapy
Drug Costs
Models, Economic
Pandemics
Pneumonia, Viral -- drug therapy
United States

2. Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents

Author(s):

Doshi, Jalpa A., author
Li, Bengxiang, author
Huo, Hairong, author
Pettit, Amy R., author
Armstrong, Katrina A., author

Publication:

Philadelphia, PA : Leonard Davis Institute of Health Economics, 2018

Subject(s):

Antineoplastic Agents -- economics
Antineoplastic Agents -- therapeutic use
Drug Costs
Financing, Personal -- statistics & numerical data
Assessment of Medication Adherence
United States

3. CMS should bolster its oversight of manufacturer-submitted average sales price data to ensure accurate Part B drug payments

Publication:

Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, December 2022

Subject(s):

Cost Control
Drug Costs
Drug Industry
Government Regulation
Medicare Part B
Prescription Fees
United States
Centers for Medicare & Medicaid Services (U.S.)

4. Calculation of potential inflation-indexed rebates for Medicare Part B drugs

Publication:

[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2017

Subject(s):

Drug Costs
Insurance, Pharmaceutical Services -- economics
Medicare Part B -- economics
United States
United States. Department of Health and Human Services

5. Competitive bidding in drug procurement: evidence from China

Author(s):

Cao, Shengmao, author
Yi, Xuejie, author
Yu, Chuan, author

Publication:

[Stanford, CA] : Stanford Institute for Economic Policy Research (SIEPR), January 2022

Subject(s):

Competitive Bidding
Drug Costs
Economics, Pharmaceutical
Models, Economic
China
United States

6. Drug discount program: federal oversight of compliance at 340B contract pharmacies needs improvement : report to Congressional requesters

Publication:

Washington, DC : United States Government Accountability Office, June 2018

Subject(s):

Drug Costs
Economics, Pharmaceutical
Pharmacies -- economics
Contract Services
United States
United States. Health Resources and Services Administration

7. Drug discount program: improvements needed in federal oversight of compliance at 340B contract pharmacies : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives

Publication:

Washington, DC : United States Government Accountability Office, July 11, 2018

Subject(s):

Drug Costs
Economics, Pharmaceutical
Pharmacies -- economics
Contract Services
Government Regulation
United States
United States. Health Resources and Services Administration

8. Drug discount program: status of agency efforts to improve 340B program oversight : testimony before the Committee on Health, Education, Labor, and Pensions, U.S. Senate

Publication:

Washington, DC : United States Government Accountability Office, May 15, 2018

Subject(s):

Drug Costs
Economics, Pharmaceutical
Government Regulation
Medicaid -- economics
United States
United States. Health Resources and Services Administration

9. Drug industry: profits, research and development spending, and merger and acquisition deals : report to Congressional requesters

Publication:

Washington, DC : United States Government Accountability Office, November 2017

Subject(s):

Drug Costs
Drug Industry -- economics
Economics, Pharmaceutical -- trends
Pharmaceutical Research -- economics
Pharmaceutical Research -- trends
United States
National Institutes of Health (U.S.)

10. Drug price increases that exceed inflation are costing Medicare Part D billions

Author(s):

Purvis, Leigh, author

Publication:

Washington, DC : AARP Public Policy Institute, June 2021

Subject(s):

Drug Costs
Inflation, Economic
Medicare Part D -- economics
Medicare Part D -- trends
Prescription Drugs -- economics
United States